EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial

Shehu U Abdullahi, Surayya Sunusi iD, Mohammed Sani Abba, Saifuddeen Sani, Hauwau Aminu Inuwa, Safiya Gambo, Awwal Gambo, Bilya Musa, Brittany V Covert Greene, Adetola A Kassim, Mark Rodeghier iD, Nafiu Hussaini iD und 4 weitere

Blood · 23.02.2023 · 141 (8) · 825-834

DOI: 10.1182/blood.2022016620 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Blood, erschienen am 23.02.2023. Verfasst von Shehu U Abdullahi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Bayero University and Aminu Kano Teaching Hospital, Kano, Nigeria. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Stroke. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NICHD NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We tested the hypothesis that fixed oral moderate-dose hydroxyurea (20 mg/kg per day) for initial treatment of secondary stroke prevention results in an 80% relative risk reduction of stroke or death when compared with fixed oral low-dose hydroxyurea (10 mg/kg per day) in a phase 3 double-blind, parallel-group, randomized controlled trial in children with sickle cell anemia (SCA) living in Nigeria. A total of 101 participants were randomly allocated to low-dose (n = 49) and moderate-dose (n = 52) hydroxyurea treatment groups. The median participant follow-up was 1.6 years (interquartile range, 1.0-2.3), with a planned minimum follow-up of 3.0 years. A total of 6 recurrent strokes and 2 deaths vs 5 recurrent strokes and 3 deaths occurred in the low- and moderate-dose groups, respectively. The incidence rate ratio (IRR) of the primary outcome measure of stroke or death in the low- and moderate-dose hydroxyurea treatment groups was 0.98 (95% confidence interval [CI], 0.32-3.00; P = .97). The trial was stopped early owing to no clinical difference in the incidence rates of the primary outcome measure. The incidence rates of recurrent strokes were 7.1 and 6.0 per 100 person-years in the low- and moderate-dose groups, respectively, (IRR, 1.18; 95% CI, 0.30-4.88; P = .74). As a measure of adherence to the oral hydroxyurea therapy, the median percent of returned pills was 3.0% and 2.6% in the low- and moderate-dose groups, respectively. No participant had hydroxyurea therapy stopped for myelosuppression. For children with SCA in low-income settings without access to regular blood transfusion therapy, initial low-dose hydroxyurea is a minimum known efficacious dose for secondary stroke prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellStrokeChildHumansHydroxyureaAntisickling AgentsNigeriaSecondary Prevention

Substanzen

HydroxyureaAntisickling Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Bayero University and Aminu Kano Teaching Hospital, Kano, Nigeria.
  • Department of Community Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria.
  • Department of Pharmacy, Aminu Kano Teaching Hospital, Kano, Nigeria.
  • Department of Administration, Aminu Kano Teaching Hospital, Kano, Nigeria.
  • Department of Internal Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria.
  • Department of Pediatrics, Murtala Mohammed Specialist Hospital, Kano, Nigeria.

ORCID-Profile: Surayya Sunusi, Mark Rodeghier, Nafiu Hussaini, Lori C Jordan, Michael R DeBaun

Förderung

  • NHLBI NIH HHS
  • NICHD NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Abdullahi, S. U., Sunusi, S., Abba, M. S., Sani, S., Inuwa, H. A., Gambo, S., Gambo, A., Musa, B., Covert Greene, B. V., Kassim, A. A., Rodeghier, M., Hussaini, N., Ciobanu, M., Aliyu, M. H., Jordan, L. C., & DeBaun, M. R. (2023). Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial. Blood, 141(8), 825-834. https://doi.org/10.1182/blood.2022016620

Vancouver

Abdullahi SU, Sunusi S, Abba MS, Sani S, Inuwa HA, Gambo S, et al. Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial. Blood. 2023;141(8):825-834. doi:10.1182/blood.2022016620

BibTeX
@article{Abdullahi2023,
  author = {Abdullahi, Shehu U and Sunusi, Surayya and Abba, Mohammed Sani and Sani, Saifuddeen and Inuwa, Hauwau Aminu and Gambo, Safiya and Gambo, Awwal and Musa, Bilya and Covert Greene, Brittany V and Kassim, Adetola A and Rodeghier, Mark and Hussaini, Nafiu and Ciobanu, Mariana and Aliyu, Muktar H and Jordan, Lori C and DeBaun, Michael R},
  title = {Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {8},
  pages = {825--834},
  doi = {10.1182/blood.2022016620}
}
Kostenlos starten →